Ultragenyx Pharmaceutical (NASDAQ:RARE) Coverage Initiated by Analysts at William Blair

William Blair assumed coverage on shares of Ultragenyx Pharmaceutical (NASDAQ:RARE - Free Report) in a report released on Wednesday, MarketBeat reports. The brokerage issued an outperform rating and a $65.00 price target on the biopharmaceutical company's stock. William Blair also issued estimates for Ultragenyx Pharmaceutical's FY2025 earnings at ($3.48) EPS, FY2026 earnings at ($1.79) EPS, FY2027 earnings at $1.75 EPS and FY2028 earnings at $4.94 EPS.

Several other equities research analysts also recently weighed in on the stock. Morgan Stanley raised their price target on shares of Ultragenyx Pharmaceutical from $64.00 to $65.00 and gave the company an "overweight" rating in a research report on Friday, May 9th. Canaccord Genuity Group lifted their target price on Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the stock a "buy" rating in a report on Tuesday, February 18th. JPMorgan Chase & Co. upped their price target on Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the company an "overweight" rating in a report on Thursday, March 27th. Piper Sandler dropped their price objective on Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an "overweight" rating on the stock in a research report on Monday, March 17th. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $118.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, February 26th. One analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $88.77.

Ultragenyx Pharmaceutical Stock Performance

Shares of NASDAQ RARE traded down $1.16 during trading hours on Wednesday, hitting $33.87. The company's stock had a trading volume of 1,631,431 shares, compared to its average volume of 838,842. The stock has a market cap of $3.20 billion, a price-to-earnings ratio of -5.34 and a beta of 0.34. Ultragenyx Pharmaceutical has a 12 month low of $29.59 and a 12 month high of $60.37. The business has a 50-day simple moving average of $35.61 and a 200-day simple moving average of $40.66.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.54) by ($0.03). Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. The company had revenue of $139.29 million for the quarter, compared to analysts' expectations of $145.98 million. During the same period in the previous year, the firm posted ($2.03) earnings per share. The firm's revenue for the quarter was up 28.0% compared to the same quarter last year. On average, equities research analysts forecast that Ultragenyx Pharmaceutical will post -5.18 EPS for the current year.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, EVP Thomas Richard Kassberg sold 6,028 shares of the company's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $42.10, for a total value of $253,778.80. Following the completion of the transaction, the executive vice president now directly owns 265,238 shares in the company, valued at $11,166,519.80. This represents a 2.22% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CAO Theodore Alan Huizenga sold 967 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $42.10, for a total value of $40,710.70. Following the completion of the sale, the chief accounting officer now directly owns 50,265 shares in the company, valued at approximately $2,116,156.50. The trade was a 1.89% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 97,415 shares of company stock worth $4,094,958 in the last three months. 5.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

A number of institutional investors and hedge funds have recently made changes to their positions in the business. California State Teachers Retirement System lifted its stake in shares of Ultragenyx Pharmaceutical by 0.3% in the 4th quarter. California State Teachers Retirement System now owns 78,051 shares of the biopharmaceutical company's stock valued at $3,284,000 after purchasing an additional 268 shares during the last quarter. Van ECK Associates Corp lifted its holdings in Ultragenyx Pharmaceutical by 18.4% during the fourth quarter. Van ECK Associates Corp now owns 1,760 shares of the biopharmaceutical company's stock worth $74,000 after buying an additional 273 shares during the period. GAMMA Investing LLC lifted its holdings in Ultragenyx Pharmaceutical by 76.2% during the first quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 323 shares during the period. Xponance Inc. boosted its position in Ultragenyx Pharmaceutical by 2.8% during the 1st quarter. Xponance Inc. now owns 12,552 shares of the biopharmaceutical company's stock valued at $455,000 after acquiring an additional 347 shares in the last quarter. Finally, BOKF NA increased its holdings in shares of Ultragenyx Pharmaceutical by 5.0% in the 4th quarter. BOKF NA now owns 7,976 shares of the biopharmaceutical company's stock valued at $336,000 after acquiring an additional 382 shares during the period. 97.67% of the stock is owned by hedge funds and other institutional investors.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.